Amgen Inc.'s British patent for its Epogen anemia treatment, the company's bestselling drug, was ruled invalid by Britain's highest court. The House of Lords in London ruled unanimously in favor of Transkaryotic Therapies Inc., which challenged the patent.
The ruling is expected to have little effect on Amgen; its Epogen patent was already due to expire in Europe on Dec. 11.
